2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, T. K, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology 2021, 5: 1432-1442. PMID: 34527850, PMCID: PMC8437220, DOI: 10.1200/po.20.00439.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerComplete responseResponse rateClinical benefit ratePartial response ratePrimary end pointOverall response rateHomologous recombination repair deficiencySerous ovarian cancerPoly (ADP-ribose) polymerase (PARP) inhibitorsPrior therapyUnacceptable toxicityEntire cohortRefractory cancerBenefit rateOvarian cancerPromising therapyPatientsBasket trialsDay 1End pointOlaparibPolymerase inhibitorsTherapyAdditional studies
1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.
Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. JAMA Dermatology 1988, 124: 878-84. PMID: 3288124, DOI: 10.1001/archderm.124.6.878.Peer-Reviewed Original ResearchConceptsAutologous bone marrow supportBone marrow supportHigh-dose combinationMarrow supportAgent chemotherapyPhase 2 doseMetastatic malignant melanomaOverall response rateMedian survivalComplete responsePartial responseSurgical resectionAdditional patientsMedian timeResidual tumorTreatment courseMalignant melanomaMarrow reconstitutionChemotherapyToxic reactionsPatientsResponse rateEntire groupMonthsDisease